#185 – Allan Sniderman, M.D.: Cardiovascular disease and why we should change the way we assess risk
“If we’re still saying the same things we said 30 years ago, it could be a problem because we should have learned how to say it better, more accurately.” —Allan Sniderman
Early risk assessment markers to delay cardiovascular disease
Identifying risk decades before disease manifests
#129 – Tom Dayspring, M.D.: The latest insights into cardiovascular disease and lipidology
“Atherogenic lipoproteins are really the issue behind clinical atherosclerotic vascular disease. … The data has just become so overwhelming.” —Tom Dayspring
#124 – AMA #15: Real-world case studies—metabolic dysregulation, low testosterone, menopause, and more
As a follow up to AMA #14 where Peter explained his framework for analyzing labs, this “Ask Me Anything” (AMA)…
Measuring cardiovascular disease risk and the importance of apoB
Millions of Americans schedule an annual physical health examination. During their visit, many can expect to get their blood drawn for…
#21 – Tom Dayspring, M.D., FACP, FNLA – Part II of V: Lipid metrics, lipid measurements, and cholesterol regulation
“If you learn nothing else today, the first thing is, lipids, for the most part, go nowhere in the human body unless they’re a passenger inside a lipoprotein.” –Tom Dayspring
Narrative glossary: lipids
A companion post for the podcast episodes with Thomas Dayspring, M.D., FACP, FNLA (October 15-19, 2018).
When does heart disease begin (and what this tells us about prevention)?
Before I get into this post I want to lay a few things out.
The straight dope on cholesterol – Part IX
In this post we’ll address the following concept: What should you eat to have the greatest chance of delaying the arrival of cardiovascular disease?
The straight dope on cholesterol – Part VIII
In this post we’ll double-click on a paper covering cholesterol and heart disease risk factors.